India: Dr Reddy’s to buy IP rights of Alchemia’s anti-coagulant drug for $17.5m

Visual sourced from Dr Reddy's website

Dr Reddy’s Laboratories Ltd has entered into an agreement with Australia’s Alchemia Ltd, a drug discovery and development company, to buy worldwide exclusive intellectual property rights of its generic anti-coagulant drug fondaparinux sodium for a cash consideration of $17.5 million (Rs 116 crore).

Continue reading this story with a subscription to DealStreetAsia.

Subscribe

Contact us for corporate subscriptions at subs@dealstreetasia.com.